BNP Paribas Financial Markets’s Ovid Therapeutics OVID Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $64.2K | Buy |
23,876
+22,884
| +2,307% | +$59K | ﹤0.01% | 4771 |
|
|
2026
Q1 | $2.2K | Buy |
992
+12
| +1% | +$21 | ﹤0.01% | 5409 |
|
|
2025
Q4 | $1.6K | Buy |
980
+18
| +2% | +$28 | ﹤0.01% | 5368 |
|
|
2025
Q3 | $1.25K | Buy |
962
+95
| +11% | +$82 | ﹤0.01% | 5215 |
|
|
2025
Q2 | $286 | Sell |
867
-66,086
| -99% | -$19.9K | ﹤0.01% | 5263 |
|
|
2025
Q1 | $20.9K | Sell |
66,953
-37,759
| -36% | -$23.2K | ﹤0.01% | 4528 |
|
|
2024
Q4 | $97.8K | Sell |
104,712
-115,689
| -52% | -$129K | ﹤0.01% | 4169 |
|
|
2024
Q3 | $260K | Buy |
220,401
+215,189
| +4,129% | +$225K | ﹤0.01% | 3152 |
|
|
2024
Q2 | $4.01K | Sell |
5,212
-26,950
| -84% | -$75K | ﹤0.01% | 3781 |
|
|
2024
Q1 | $98.1K | Buy |
32,162
+13,756
| +75% | +$46K | ﹤0.01% | 3438 |
|
|
2023
Q4 | $59.3K | Buy |
18,406
+9,756
| +113% | +$33.3K | ﹤0.01% | 3526 |
|
|
2023
Q3 | $33.2K | Sell |
8,650
-6,855
| -44% | -$24.6K | ﹤0.01% | 3517 |
|
|
2023
Q2 | $50.9K | Buy |
15,505
+15,504
| +1,550,400% | +$52.6K | ﹤0.01% | 3467 |
|
|
2023
Q1 | $3 | Hold |
1
| – | – | ﹤0.01% | 3834 |
|
|
2022
Q4 | $2 | Sell |
1
-158
| -99% | -$269 | ﹤0.01% | 4020 |
|
|
2022
Q3 | $293 | Sell |
159
-914
| -85% | -$1.91K | ﹤0.01% | 4576 |
|
|
2022
Q2 | $2.31K | Buy |
1,073
+1,010
| +1,603% | +$2.44K | ﹤0.01% | 3865 |
|
|
2022
Q1 | $198 | Hold |
63
| – | – | ﹤0.01% | 4079 |
|
|
2021
Q4 | $202 | Hold |
63
| – | – | ﹤0.01% | 4147 |
|
|
2021
Q3 | $212 | Sell |
63
-3,371
| -98% | -$12.3K | ﹤0.01% | 3951 |
|
|
2021
Q2 | $13.4K | Sell |
3,434
-2,440
| -42% | -$9.63K | ﹤0.01% | 3650 |
|
|
2021
Q1 | $23.6K | Sell |
5,874
-2,840
| -33% | -$9.43K | ﹤0.01% | 3726 |
|
|
2020
Q4 | $20.1K | Sell |
8,714
-1,048
| -11% | -$4.88K | ﹤0.01% | 3848 |
|
|
2020
Q3 | $56K | Buy |
9,762
+8,158
| +509% | +$54.6K | ﹤0.01% | 3421 |
|
|
2020
Q2 | $11.8K | Buy |
1,604
+1,534
| +2,191% | +$7.17K | ﹤0.01% | 3633 |
|
|
2020
Q1 | $209 | Hold |
70
| – | – | ﹤0.01% | 4181 |
|
|
2019
Q4 | $290 | Sell |
70
-1,481
| -95% | -$4.68K | ﹤0.01% | 4288 |
|
|
2019
Q3 | $5.03K | Hold |
1,551
| – | – | ﹤0.01% | 4275 |
|
|
2019
Q2 | $2.87K | Sell |
1,551
-1,248
| -45% | -$2.23K | ﹤0.01% | 4290 |
|
|
2019
Q1 | $4.95K | Buy |
2,799
+2,549
| +1,020% | +$6.38K | ﹤0.01% | 4079 |
|
|
2018
Q4 | $605 | Sell |
250
-172
| -41% | -$785 | ﹤0.01% | 3985 |
|
|
2018
Q3 | $2.39K | Hold |
422
| – | – | ﹤0.01% | 4233 |
|
|
2018
Q2 | $3.29K | Sell |
422
-1,884
| -82% | -$16.2K | ﹤0.01% | 4193 |
|
|
2018
Q1 | $16.3K | Buy |
2,306
+1,263
| +121% | +$10.2K | ﹤0.01% | 3951 |
|
|
2017
Q4 | $10.3K | Buy |
1,043
+550
| +112% | +$5.05K | ﹤0.01% | 4028 |
|
|
2017
Q3 | $4.22K | Sell |
493
-37
| -7% | -$308 | ﹤0.01% | 4004 |
|
|
2017
Q2 | $5.56K | Buy |
+530
| New | +$6.92K | ﹤0.01% | 4021 |
|
Other funds holding OVID
AAA
VCM
SCM
SC
BNP Paribas Financial Markets's OVID Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Ovid Therapeutics (OVID) stake by 2,307% in Q2 2026, buying an estimated $59K and bringing the position to 23,876 shares worth $64.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4771.
BNP Paribas Financial Markets first reported a position in OVID in Q2 2017 and has held it in 37 quarters since. The position peaked at $260K in Q3 2024. 89 funds tracked by Wall St. Rank hold OVID as of Q2 2026.
- BNP Paribas Financial Markets held 23,876 shares of Ovid Therapeutics worth $64.2K as of Q2 2026.
- BNP Paribas Financial Markets bought 22,884 Ovid Therapeutics shares in Q2 2026, an estimated $59K.
- Ovid Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4771 holding.
- BNP Paribas Financial Markets first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 37 quarters since.
- BNP Paribas Financial Markets's Ovid Therapeutics position peaked at $260K in Q3 2024.
- 89 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.